国家: 亚美尼亚
语言: 英文
来源: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
nefopam (nefopam hydrochloride)
Biocodex
nefopam (nefopam hydrochloride)
10mg/ml
solution for injection
Prescription
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT ACUPAN ® 20 MG, SOLUTION FOR INJECTION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Nefopam (hydrochloride) ................................................................. 20.00 mg For one ampoule of 2 ml. Excipient with known effect: none For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection in ampoule. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Acupan is indicated in adults for the symptomatic treatment of acute painful conditions, especially post-operative pains. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION As for any antipain treatment, the dosage must be adapted to pain intensity and patient response. _POSOLOGY _ IM route: Acupan should be administered by deep intramuscular route. The usual recommended dose is 20 mg per injection. If necessary, it can be repeated every 6 hours without exceeding the total dose of 120 mg/day. IV route: Acupan should be administered by slow intravenous infusion in more than 15 minutes, the patient laying down in order to avoid some side effects such as nausea, dizziness, sweat. The usual recommended unique dose is 20 mg per injection. If necessary, it can be repeated every 4 hours, without exceeding 120 mg/day. Paediatric population: the safety and efficacy of Acupan in children below 15 years of age have not been established. _METHOD OF ADMINISTRATION _ Acupan can be administered in the usual solutions for perfusion (isotonic solution of sodium chloride or glucose solution). It is recommended to avoid mixing Acupan and other injectable drugs in the same syringe. 4.3. CONTRAINDICATIONS Hypersensitivity to the active ingredient or to any of the excipients listed in section 6.1. Children below 15 years of age in of the absence of clinical studies. Convulsions or previous history of convulsions. Risk of urinary retention linked to uretroprostatic disorders. Risk of acute angle glaucoma. 4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE _SP 阅读完整的文件